What's the Best Way to Approach CCUS Management?

By Blood Cancer Talks - Last Updated: August 30, 2023

In this episode of “Blood Cancer Talks,” Uma Borate, MBBS, of the Ohio State University, joins the hosts to discuss clonal cytopenias of unknown significance (CCUS).

Dr. Borate outlines the diagnosis process, as well as monitoring and management strategies for CCUS.

The episode highlights CCUS risk stratification approaches, scoring systems, and recent research on predicting the likelihood of CCUS transformation to a myeloid neoplasm. Dr. Borate and the hosts also discuss studies on the germline predisposition to clonal hematopoiesis, and how cancer treatments impact clonal hematopoiesis.

Additionally, Dr. Borate and the hosts cover the IMPACT study, which evaluated canakinumab for the prevention of progression to cancer in patients with CCUS, as well as a study of ivosidenib in patients with CCUS and mutations in IDH1.

This podcast originally appeared on Blood Cancer Talks.

What are the Controversies Surrounding MRD in Blood Cancers?

What are the Risk Factors, Treatment Options for Essential Thrombocythemia?

HMAs Are ‘Cornerstone’ in High-Risk MDS Treatment, Says Jamile Shammo, MD

Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL

Dr. Samer Al Hadidi Discusses CAR-T MM Data Presented at the FDA ODAC Meeting

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

What's the Best Way to Approach CCUS Management?

Related